1. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J,2020
2. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy;J Am Coll Cardiol,2019
3. The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer;Seidah;J Lipid Res,2021
4. Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review;McClintick;Curr Opin Lipidol,2023
5. PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo controlled and active-controlled phase 2 trial;Koren;Lancet Diabetes Endocrinol,2023